-
JNNP: Evidence-based prevention of Alzheimer's disease: 243 prospective observational studies and 153 systematic evaluation and meta-analysis of randomized controlled trials.
Time of Update: 2020-09-25
Yu J, Xu W, Tan C, et al Evidence-base prevention of Alzheimer's disease: system review and meta-analysis of 243 observational prospective studies and 153 randomised trials Journal of Neurology, Neurosurgery and PsimsyPublished Online First: 20 July 2020.
-
The technology is not "stunning", but it can't stop Musk's brain-machine plans from rushing to commercialization.
Time of Update: 2020-09-25
August 28th, at the launch of the Neuralink Brain-Computer Interaction Project, Musk demonstrated the latest brain-computer interface (BCI) devices - coin-sized hardware, The Link, a microscope electrode about a third of the diameter of hair, Neural Lace, and surgical robots.
-
JAHA: The role of the substitin metal protease 9 in circulating ischemic stroke after mezzanine-related vertebral arteries.
Time of Update: 2020-09-25
Spontaneous vertebral arterial mezzanine (VAD) is an important cause of post-circulatory ischemic stroke (PCS), but its pathogenesis is not yet clear.
-
EBV-specific T-cell immunotherapy ATA188 treats multiple sclerosis: positive results were achieved in all dose groups.
Time of Update: 2020-09-25
latest data show that ATA188 has good tolerance in all four dosage groups, improving persistent disease at any point in time, and increasing numbers of patients exhibit continuous disability improvement (SDI) as doses increase.
-
NEJM: Analysis of the efficacy of sodium benzoate-taurine glycol in the treatment of amyotrophic lateral sclerosis.
Time of Update: 2020-09-25
The main outcome of this study was the rate of decline of the total score of the revised amyotrophic lateral sclerosis function scale (ALSFRS-R; the higher the score indicates better function), the secondary outcome was isometremic force, plasma phosphate axon surrosis H sub-base level drop, lung capacity, death, tracheotomy or permanent air conditioning; the study screened 177 ALS patients and randomly assigned 137 people to receive sodium benzoate-taurine glycol (89 participants) or placebo (48 participants).
-
SLEEP 2020: DAYVIGO (lemborexant) treats adult insomnia, and Phase III clinically confirms its effectiveness and safety.
Time of Update: 2020-09-25
Eisai Pharmaceuticals today published the main results of clinical studies in SUNRISE 1 and SUNRISE 2 that analyzed the long-term efficacy and safety of DAYVIGO's treatment of insomniacs aged 65 and over.
-
Acta Neuropathology: Brain pathology is associated with the rate and variability of motor function decline in older adults.
Time of Update: 2020-09-25
In different models, AD pathology, loss of black neurons, Lewy small body, large area infarction, atherosclerosis, fine arteriosclerosis, and cerebral amyloid vascular disease were associated with faster motor decline.
-
Acta Neuropathologica: Tau deposition characteristics in chronic traumatic encephalopathy (CTE): Application of McKee-CTE phased solutions.
Time of Update: 2020-09-25
The authors studied the relationship between McKee-CTE phased programmes and semi-quantitative and quantitative assessments of local p-tau pathology, age of death, dementia and the age of American football (average age 61.86, standard deviation 18.90) in 366 male brain bodies diagnosed with CTE.
-
JCEM: Association between body mass index and serum uric acid and dementia.
Time of Update: 2020-09-25
Recent studies have shown that higher BMI and serum uric acid levels are associated with a lower risk of dementia.
participants with uric acid levels in the lowest five-digit range also had a 25 percent lower risk of developing dementia (HR-0.75, 95 percent CI: 0.64-0.87).
-
The Lancet Neurology: The safety, toerability and effectiveness of oral Atogpant treatment for thyset migraines in adults: a double-blind, randomized phase 2b/3 trial.
Time of Update: 2020-09-25
Atogepant is an oral small molecule calcitonin gene-associated peptide (CGRP) peptide antagonist, and a series of studies have been published on Atogpant's treatment of migraines.
Safety, tolerability, and efficacy of orally agency atogepant for the prevention of episodic migraine in adults: a double-blind, randomized phase 2b/3 trial Goadsby, Peter J et al.
-
Acta Neuropathologica: Plasma p-tau 181 accurately predicts the pathology of Alzheimer's disease and improves the clinical characteristics of cognitive decline at least 8 years before death.
Time of Update: 2020-09-25
, however, an increasing number of clinical assessments of AD are complemented by neuropathologically proven biomarkers that reflect the pathological characteristics of A-beta and tau, thereby improving the accuracy of diagnosis of AD in life.
-
JNNP: Professor Tulip Tai of Huashan Hospital led the development of international guidelines for evidence-based prevention of Alzheimer's disease.
Time of Update: 2020-09-25
According to the World Alzheimer's Disease 2018 Report, one dementia patient worldwide is born every three seconds. currently, there are at least 50 million people with dementia worldwide, and that n
-
SLEEP 2020: The gospel of insomniacs, Daridorexant's Phase III clinical progress.
Time of Update: 2020-09-25
Dr Thomas Roth, director of the Sleep Disorders and Research Centre at Henry Ford Hospital, commented: "Daridorexant is a new dual Orexin subjecttagonist whose pharmacodynamic and pharmacodynamic characteristics are optimized for sleep seizures and duration of action to improve nighttime efficacy without residual effects." Phase III clinical trials are designed to assess the effectiveness and safety of the dridorexant treatment for patients with moderate to severe insomnia.
-
Curr Biol: Still staying up late? Sleep patterns may help predict 'dementia' and are more likely to 'get silly' if you don't sleep well, new study finds
Time of Update: 2020-09-25
However, a recent study published in Current Biology by researchers in psychology and neuroscience at the University of California, Berkeley, found that "good sleep" may be an important way to deal with Alzheimer's disease today, and that poor sleep quality is consistent with an increase in toxic protein accumulation.
-
JAHA: Relationship between cardiovascular risk burden and disability risk and progression.
Time of Update: 2020-09-24
A recent study published in JAHA, an authoritative journal in the field of cardiovascular disease, looked at the association between cardiovascular risk burden and disability risk and progression assessed by the Flemingham Comprehensive Cardiovascular Risk Score (FGCRS) and estimated the extent to which CVD and cognitive decline mediated this association.
-
JNNP: The efficacy and safety of laconamide-assisted treatment of primary systemic strong-straight convulsive epilepsy: a double-blind, randomized, placebo-controlled trial.
Time of Update: 2020-09-24
-blind, placebo-controlled trial (SP0982; NCT02408523) was conducted to evaluate the effectiveness and safety of PGTCS in lakosemi-assisted treatment of IKE patients (4 years of age).
to ensure a minimum exposure for safety assessments, patients must complete at least 6 weeks of trial treatment.
-
JNNP: Important brain biomarker for trauma seizures: preliminary report on epileptic bioinficial studies of anti-epileptic drug therapy (EpiBioS4Rx).
Time of Update: 2020-09-24
First, the author carried out a variance analysis, taking the thinning of the cort belt and the deficiency of local capacity under the cort matter (at each python) as the factor variable, taking the group (no seizures, early seizures, late seizures) as the argument, controlling age, sex, severity of injury, injury and normalization of brain capacity the day after MR diagnosis.
-
JAMA Neurol: Effects of selective 5-serotonin reuptake inhibitors on stroke recurrence and depressive symptoms in stroke-surviving patients.
Time of Update: 2020-09-24
Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat post-stroke depression, but studies have found that SSRIs can lead to an increased risk of cerebral hemorrhage (ICH) in the general population.
-
JNNP: Guillain-Barré syndrome anti-neurothycoside antibodies associated with SARS-CoV-2 infection.
Time of Update: 2020-09-24
although there is little information on the neurological symptoms of COVID-19, there are reports describing Greene-Barre syndrome (GBS) as an acute symptom of SARS-CoV-2.
so far, anti-neuro-glycoside antibody detection (anti-GM1, anti-GD1a, and anti-GD1b) for different neural glycoside lipids represents the novelty of GBS associated with SARS-CoV-2 infection.
-
JAMA Neurol: Study of risk factors for relapsed transsexual holistic amnesia.
Time of Update: 2020-09-24
study, patients with relapsed temporary total amnesia had a lower age for the first time, and a higher proportion of migraines and familial migraines.
